Send to printer »

GEN News Highlights : Sep 19, 2006

Molecule to Treat Various Risk Factors of Cardiometabolic Disease Goes into Clinic

Genfit reports the entry into Phase I trials of GFT505, the company’s molecule for the simultaneous treatment of several risk factors of cardiometabolic disease.

According to a Genfit spokesperson, GFT505, a multimodal, pluripotent compound, acts on the molecular level by activating PPAR (peroxisome proliferator-activated receptors) nuclear receptors, which play a central role in the regulation of lipid metabolism and the control of glycemia.

“With a completely original profile—Pan-sPPARm, selective PPAR modulator, with a preferential action on the PPAR alpha family—and evaluated by Genfit’s proprietary SNuRM technology platform, GFT505 targets a wide range of indications: mixed dyslipidemia, type II diabetes, and atherosclerosis,” explains Dean Hum, vp and CSO.